Activity Overview
Small cell lung cancer (SCLC) is a highly aggressive malignancy. It accounts for less than 20% of lung cancers but contributes disproportionately to lung cancer–related mortality. Prognosis is particularly poor for patients who develop extensive-stage (ES-)SCLC. Recent regulatory approvals and practice-changing data are redefining the ES-SCLC treatment landscape and raising new considerations for selecting therapy and optimally incorporating emerging agents into practice.
Show Me the Data®: Redefining Extensive-Stage SCLC—Emerging Therapies, CNS Considerations, and the Radiation Oncologist’s Evolving Role was held in conjunction with the 2026 American Society for Radiation Oncology Annual Meeting. It features a panel of radiation oncology and medical oncology specialists who will review recent developments and highlight practical strategies to incorporate systemic therapies and radiation therapy to optimize outcomes for patients with ES-SCLC.
This educational activity is an archive of the live presentation held on September 28, 2026.
Target Audience
This educational activity is directed toward radiation oncologists, medical oncologists, and the multidisciplinary team—including nurse practitioners, physician assistants, oncology nurses, and pharmacists—involved in the management of patients with ES-SCLC, including those with brain metastases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate emerging systemic therapies for extensive-stage SCLC across lines of treatment
- Apply evidence for the intracranial activity of emerging systemic agents to individualize treatment in extensive-stage SCLC
- Differentiate and co-manage treatment-related adverse events associated with novel therapies for extensive-stage SCLC
Kristin Higgins, MD
Clinical Professor, Department of Radiation Oncology
Chief Clinical Officer
City of Hope Cancer Center Atlanta
Newnan, GA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca Pharmaceuticals, Daiichi Sankyo, Picture Health
Alissa J. Cooper, MD
Physician, Medical Oncology
Dana-Farber Cancer Institute
Instructor in Medicine
Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Gilead Sciences, Novartis, Regeneron; Grant/Research Funding: AbbVie, Amgen, Daiichi Sankyo, IDEAYA Biosciences, Merck, Monte Rosa Therapeutics, Roche
Percy Lee, MD, MBA, FASTRO
Professor and Vice Chair of Clinical Research
Medical Director, Radiation Oncology, Orange County and Coastal Regions
City of Hope National Medical Center
Duarte, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Genentech/Roche, Johnson & Johnson, Varian/Siemens; Grant/Research Funding: Varian/Siemens
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.